Barclays’s Oramed Pharmaceuticals ORMP Stock Holding History

Barclays’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$67.9K	Buy	19,966 +13,049	+189%	+$44.3K	﹤0.01%	4190
2025 Q4	$19.7K	Sell	6,917 -6,281	-48%	-$16.2K	﹤0.01%	4872
2025 Q3	$34.8K	Hold	13,198	–	–	﹤0.01%	4852
2025 Q2	$29.7K	Hold	13,198	–	–	﹤0.01%	4791
2025 Q1	$28.2K	Hold	13,198	–	–	﹤0.01%	4736
2024 Q4	$31.9K	Sell	13,198 -41	-0.3%	-$97	﹤0.01%	4853
2024 Q3	$32.3K	Hold	13,239	–	–	﹤0.01%	4828
2024 Q2	$34K	Hold	13,239	–	–	﹤0.01%	4336
2024 Q1	$38.7K	Hold	13,239	–	–	﹤0.01%	4668
2023 Q4	$30.6K	Sell	13,239 -5,167	-28%	-$11K	﹤0.01%	4843
2023 Q3	$48K	Buy	18,406 +5,167	+39%	+$16.3K	﹤0.01%	3888
2023 Q2	$47.4K	Sell	13,239 -7,410	-36%	-$23.8K	﹤0.01%	3859
2023 Q1	$45K	Sell	20,649 -19,129	-48%	-$60.8K	﹤0.01%	4477
2022 Q4	$479K	Buy	39,778 +18,235	+85%	+$142K	﹤0.01%	3342
2022 Q3	$140K	Buy	21,543 +1,724	+9%	+$14K	﹤0.01%	3380
2022 Q2	$90K	Sell	19,819 -6,510	-25%	-$34.8K	﹤0.01%	3814
2022 Q1	$227K	Sell	26,329 -28,553	-52%	-$293K	﹤0.01%	3341
2021 Q4	$783K	Buy	54,882 +23,740	+76%	+$496K	﹤0.01%	2978
2021 Q3	$685K	Sell	31,142 -5,339	-15%	-$90.9K	﹤0.01%	3014
2021 Q2	$488K	Buy	36,481 +15,998	+78%	+$183K	﹤0.01%	3086
2021 Q1	$208K	Buy	20,483 +16,660	+436%	+$137K	﹤0.01%	3689
2020 Q4	$16K	Hold	3,823	–	–	﹤0.01%	4701
2020 Q3	$10K	Hold	3,823	–	–	﹤0.01%	5013
2020 Q2	$13K	Hold	3,823	–	–	﹤0.01%	5288
2020 Q1	$12K	Hold	3,823	–	–	﹤0.01%	5778
2019 Q4	$20K	Sell	3,823 -37,375	-91%	-$140K	﹤0.01%	5987
2019 Q3	$131K	Buy	41,198 +12	+0%	+$40	﹤0.01%	5275
2019 Q2	$148K	Hold	41,186	–	–	﹤0.01%	5373
2019 Q1	$150K	Hold	41,186	–	–	﹤0.01%	5050
2018 Q4	$124K	Hold	41,186	–	–	﹤0.01%	4901
2018 Q3	$201K	Hold	41,186	–	–	﹤0.01%	4997
2018 Q2	$306K	Hold	41,186	–	–	﹤0.01%	4366
2018 Q1	$268K	Hold	41,186	–	–	﹤0.01%	4571
2017 Q4	$371K	Hold	41,186	–	–	﹤0.01%	4134
2017 Q3	$409K	Buy	41,186 +11,261	+38%	+$97.1K	﹤0.01%	3809
2017 Q2	$233K	Hold	29,925	–	–	﹤0.01%	4245
2017 Q1	$184K	Hold	29,925	–	–	﹤0.01%	4409
2016 Q4	$183K	Hold	29,925	–	–	﹤0.01%	4286
2016 Q3	$217K	Hold	29,925	–	–	﹤0.01%	3908
2016 Q2	$250K	Hold	29,925	–	–	﹤0.01%	3761
2016 Q1	$180K	Hold	29,925	–	–	﹤0.01%	3915
2015 Q4	$239K	Buy	+29,925	New	+$227K	﹤0.01%	3765
2014 Q2	–	Sell	-10,989	Closed	-$121K	–	7750
2014 Q1	$121K	Buy	+10,989	New	+$185K	﹤0.01%	5274

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Barclays's ORMP Position: Q1 2026 in Review

Barclays increased its Oramed Pharmaceuticals (ORMP) stake by 189% in Q1 2026, buying an estimated $44.3K and bringing the position to 19,966 shares worth $67.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4190.

Barclays first reported a position in ORMP in Q1 2014 and has held it in 43 quarters since. The position peaked at $783K in Q4 2021. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Barclays held 19,966 shares of Oramed Pharmaceuticals worth $67.9K as of Q1 2026.
Barclays bought 13,049 Oramed Pharmaceuticals shares in Q1 2026, an estimated $44.3K.
Oramed Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4190 holding.
Barclays first reported a position in Oramed Pharmaceuticals in Q1 2014 and has held it in 43 quarters since.
Barclays's Oramed Pharmaceuticals position peaked at $783K in Q4 2021.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.